ESC 365 - Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

ESC Premium Access

Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.

Session: Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Topic: Secondary Prevention

Speaker: Doctor N. del-Cuerpo-Salinas (Sant Joan d'Alacant, ES)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Nicolas del-Cuerpo-Salinas

UNIVERSITY HOSPITAL SAN JUAN DE ALICANTE, Sant Joan d'Alacant (Spain)

0 follower

4 more presentations in this session

State-of-the-art lecture on obesity and pre-diabetes: where do we stand today on prevention and treatment?

Speaker: Professor E. Prescott (Copenhagen, DK)

Are metabolically healthy obese individuals really a benign cardiovascular group? An analysis of 162,590 participants with measures of arterial stiffness in UK BIOBANK

Speaker: Doctor R. Ananda (Melbourne, AU)

Association between normal range UACR and insulin resistance and prediabetes among US adults:

Speaker: Miss S. Wu (Beijing, CN)

Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial

Speaker: Professor S. Kahn (Seattle, US)

Access the full session

Obesity and pre-diabetes: where do we stand today on prevention and treatment?

Speakers: Doctor N. del-Cuerpo-Salinas, Professor E. Prescott, Doctor R. Ananda, Miss S. Wu, Professor S. Kahn

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources